TCGA-GV-A3QF-01A-31R-A22U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.26938239
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.350
- CHOLESTEROL_HOMEOSTASIS+0.320
- SPERMATOGENESIS+0.270
- FATTY_ACID_METABOLISM+0.240
- MTORC1_SIGNALING+0.240
- XENOBIOTIC_METABOLISM+0.240
- PEROXISOME+0.200
- APICAL_SURFACE+0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.180
- GLYCOLYSIS+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.490
- INTERFERON_GAMMA_RESPONSE-0.490
- ALLOGRAFT_REJECTION-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- UV_RESPONSE_DN-0.330
- ANGIOGENESIS-0.290
- IL2_STAT5_SIGNALING-0.280
- WNT_BETA_CATENIN_SIGNALING-0.270
- HEDGEHOG_SIGNALING-0.240
- MYC_TARGETS_V1-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R286 | — | — | 0.796 |
| 2 | SRR8613749 | — | C | 0.793 |
| 3 | TCGA-33-6738-01A-11R-1949-07 | — | cohortA4 | 0.793 |
| 4 | TCGA-BT-A42C-01A-11R-A23N-07 | — | — | 0.784 |
| 5 | ERR2278863 | — | — | 0.760 |
| 6 | SRR1516065 | — | — | 0.752 |
| 7 | TCGA-CV-A6JY-01A-11R-A31N-07 | — | — | 0.747 |
| 8 | AUR-AG12-TTM1-A-1-1-R-A743-41 | — | C | 0.741 |
| 9 | TCGA-QK-A8ZA-01A-11R-A39I-07 | — | — | 0.741 |
| 10 | TCGA-BB-4227-01A-01R-1873-07 | — | — | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| HYPOXIA | 0.080 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.030 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |